# FDA Approves Veligrotug (Lumvoa) for Thyroid Eye Disease Regardless of Disease Activity or Duration

> fda · REPORTED · 2026-06-26

The FDA approved veligrotug-vvze (Lumvoa) on June 26, 2026, for thyroid eye disease based on the phase 3 THRIVE and THRIVE-2 trials, making it the first TED therapy labeled for both active and chronic disease and the first in its class to show significant effects on both diplopia response and complete diplopia resolution. Viridian announced an immediate U.S. launch with a patient support program.

- Company: Viridian Therapeutics
- Sector: therapeutics
- Primary source: https://www.hcplive.com/view/8-fda-headlines-you-missed-in-june-2026

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.